NEW YORK, Dec. 4 NeoStem, Inc.(NYSE Alternext US: NBS), which is pioneering the pre-disease collection,processing and long-term storage of adult stem cells for future medical need,today announced that it has reached a major milestone in its current businessplan with the opening of the first ever collection center for collection ofadult stem cells by the general public for future medical need in New YorkCity and has chosen Bruce Yaffe, M.D., Yaffe, Ruden and Associates (founderand partner), a vibrant Manhattan based medical practice, to performcollections in this important market.
"My wife, Karen, and I jumped on the opportunity to be among the first inNew York City to undergo this painless stem cell collection process. We arevery excited about having made this important decision, taking out a"bioinsurance" policy to have ready access in the future to different ASCtherapies that are developing. This includes the possibility of having acomplete bone marrow transplantation if that were ever necessary," stated Dr.Yaffe. "The future possibilities of how this bank of stem cells may be usedare potentially endless, especially given the new outlook on adult stem cellresearch that is expected to occur under the administration of President ElectObama," Dr. Yaffe added.
Robin Smith, MD MBA, NeoStem's Chairman and Chief Executive Officercommented, "We are excited to have teamed up with Dr. Bruce Yaffe to provideour adult stem cell collection services in the New York Metropolitan area.This New York center, due to its strategic location in midtown Manhattan, isideally suited to serve all of New York City as well as the surrounding Tri-State area. We are currently embarking on a Tri-State area public awarenessprogram to inform the general population, including the 1200 patients per weekwho presently receive medical care services from Yaffe, Ruden and Associates,about the importance of stem cell collection and long term storage.
"We, at NeoStem continue to be encouraged by the success stories occurringaround the globe involving adult stem cell therapies, and are confident in ourbelief that having readily available adult stem cells that are harvested whilethey are abundant and healthy, is an integral component to successfulpotential life saving therapies. Evidence of the enormous potential that adultstem cells possess, is evident in the recently reported case involving ClaudiaCastillo, a Barcelona resident who had recently undergone surgery, and was thefirst person to receive a new branch of her windpipe, which had beenpreviously destroyed by Tuberculosis, grown in a lab using her own adult stemcells. According to her doctors, without this breakthrough operation this pastJune, her lung would have had to have been removed. Today, after theoperation, Claudia reportedly is able to look after her two children and cancontinue to lead a normal life."http://www.timesonline.co.uk/tol/life_and_style/health/article5183686.ece?print=yes&randnum=1228238717140 (Due to the length of the URL, please cut andpaste into browser.)
Dr. Yaffe, who is a board-certified internist and a digestive diseasesubspecialist, further added, "At Yaffe, Ruden and Associates, we work hard tostay ahead of the medical curve and use the latest medical equipment andmedical information to help our patients stay healthy and be prepared for thefuture. We pride ourselves on giving individualized care to the over 1200patients we treat each week. We use standard of care as well as incorporatenew technologies that become available as data emerges on new advancements inmedicine. We are pleased and excited to bring the NeoStem process to ourpatients and give them the opportunity to secure "bio-insurance" for theirmedical futures. There are over 2000 clinical trials that are using anindividuals own stem cells for diseases such as heart disease, Lupus, MS,Crohn's disease and diabetes, just to name a few."
Appointments for stem cell collection can be arranged by calling our tollfree number 1.888.783.6226 or by contacting us via our website atwww.neostem.com.
About NeoStem, Inc.
NeoStem is developing a network of adult stem cell collection centers thatare focused on enabling people to donate and store their own (autologous) stemcells when they are young and healthy for their personal use in times offuture medical need. The Company has also entered into research anddevelopment through the acquisition of a worldwide exclusive license totechnology to identify and isolate VSELs (very small embryonic-like stemcells), which have been shown to have several physical characteristics thatare generally found in embryonic stem cells.
This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995. Forward-lookingstatements reflect management's current expectations, as of the date of thispress release, and involve certain risks and uncertainties. The Company'sactual results could differ materially from those anticipated in theseforward-looking statements as a result of various factors. Factors that couldcause future results to materially differ from the recent results or thoseprojected in forward-looking statements include whether the New York Citycollection center becomes a successful collection facility and those set forthunder "Risk Factors" described in the Company's periodic filings with theSecurities and Exchange Commission.Contact: NeoStem, Inc. Robin Smith, Chief Executive Officer T: 212-584-4180 E: [email protected]
SOURCE NeoStem, Inc.